文献速递认知障碍与痴呆

Semorinemab在轻中度阿尔茨海默病参与者中的安全性和有效性的随机II期研究:Lauriet

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
PubMed 文献 · Neurology · 2023-08-29

Lauriet是一项II期随机、安慰剂对照、双盲研究,评估抗tau单克隆抗体semorinemab在轻中度阿尔茨海默病中的疗效和安全性。共272例参与者随机,238例纳入改良意向治疗人群。第49周时,semorinemab组ADAS-Cog11下降较安慰剂组减少42.2%(-2.89分,95%CI -4.56至-1.21,p=0.0008),但ADCS-ADL、MMSE和CDR-SB未见显著疗效。研究按预设共同主要终点为阴性,semorinemab安全且耐受性良好。

要点

  • semorinemab组第49周ADAS-Cog11下降较安慰剂组减少42.2%(-2.89分,95%CI -4.56至-1.21,p=0.0008)。
  • ADCS-ADL评分变化组间绝对差异为-0.83分(95%CI -3.39至1.72,p=0.52),无显著疗效。
  • MMSE和CDR-SB等次要终点未见显著治疗效应;semorinemab安全且耐受性良好。

核心结论

  • 基于预设共同主要终点,本研究为阴性。
  • semorinemab对ADAS-Cog11所测认知有显著效应,但该效应未延伸至功能或整体结局的改善。
  • 这些结果可能需要进一步探索semorinemab或其他抗tau疗法在轻中度阿尔茨海默病中的应用。
  • 本研究提供I级证据表明semorinemab不能减缓轻中度阿尔茨海默病患者的功能衰退。

研究设计与样本

  • Lauriet是一项II期随机、安慰剂对照、双盲研究,纳入轻中度阿尔茨海默病参与者。
  • 双盲期内参与者每4周静脉接受semorinemab 4500 mg或安慰剂,持续48或60周。
  • 随后可选开放标签扩展期中,参与者每4周接受semorinemab 4500 mg,最长96周。
  • 2018年12月3日至2020年2月27日期间,筛查624人,随机272例参与者,238例纳入改良意向治疗人群。
  • 改良意向治疗人群定义为接受至少1剂研究药物并完成基线和至少1次基线后评估的参与者。

主要发现

  • 第49周时,semorinemab组ADAS-Cog11下降较安慰剂组减少42.2%(-2.89分,95%CI -4.56至-1.21,p=0.0008)。
  • ADCS-ADL评分自基线变化在两组间的绝对差异为-0.83分(95%CI -3.39至1.72,p=0.52),未见治疗效应。
  • MMSE和CDR-SB等次要终点未见治疗效应。
  • semorinemab安全且耐受性良好。

关键数值与推荐

  • 共同主要疗效终点为ADAS-Cog11和ADCS-ADL自基线至第49周或第61周的变化。
  • 次要疗效终点包括MMSE和CDR-SB自基线的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 基于预设共同主要终点,本研究为阴性。
  • semorinemab对ADAS-Cog11所测认知的显著效应未延伸至功能或整体结局的改善。
  • 这些结果可能需要进一步探索semorinemab或其他抗tau疗法在轻中度阿尔茨海默病中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Accumulation of tau pathology in Alzheimer disease (AD) correlates with cognitive decline. Anti-tau immunotherapies were proposed as potential interventions in AD. While antibodies targeting N-terminal tau failed to demonstrate clinical efficacy in prodromal-to-mild AD, their utility at other disease stages was not evaluated in prior studies. Lauriet is a phase 2 study of an anti-tau monoclonal antibody, semorinemab, in patients with mild-to-moderate AD. METHODS: The phase 2 Lauriet study included a randomized, placebo-controlled, double-blind period, during which participants with mild-to-moderate AD received 4,500 mg of IV semorinemab or placebo every 4 weeks for 48 or 60 weeks. Participants who chose to continue in the subsequent optional open-label extension received 4,500 mg of semorinemab every 4 weeks for up to 96 weeks. Coprimary efficacy endpoints were change from baseline to week 49 or 61 on the 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale. Secondary efficacy endpoints included change from baseline on the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB). Safety, pharmacokinetics, and pharmacodynamic effects were also evaluated. RESULTS: Between December 3, 2018, and February 27, 2020, 624 individuals were screened, 272 participants were randomized, and 238 were included in the modified intent-to-treat population (received ≥1 dose(s) of study medication and underwent baseline and ≥1 postbaseline assessment(s)). Baseline characteristics were well balanced. At week 49, the semorinemab arm demonstrated a 42.2% reduction (-2.89 points, 95% CI -4.56 to -1.21, p = 0.0008) in decline on the ADAS-Cog11 (coprimary endpoint) relative to the placebo arm. However, no treatment effects were observed on the ADCS-ADL scale (coprimary endpoint; absolute difference between the 2 treatment arms in the ADCS-ADL score change from baseline of -0.83 points, 95% CI -3.39 to 1.72, p = 0.52) or on the MMSE or CDR-SB (secondary endpoints). Semorinemab was safe and well tolerated. DISCUSSION: Based on the results of the prespecified coprimary endpoints, this study was negative. While semorinemab had a significant effect on cognition measured by the ADAS-Cog11, this effect did not extend to improved functional or global outcomes. These results may warrant further exploration of semorinemab or other anti-tau therapies in mild-to-moderate AD. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that semorinemab does not slow functional decline in patients with mild-to-moderate AD. TRIAL REGISTRATION INFORMATION: The Lauriet study is registered on ClinicalTrials.gov, NCT03828747, and EudraCT 2018-003398-87.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Monteiro C, Toth B, Brunstein F, et al. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet. Neurology. 2023. PMID: 37643887. doi:10.1212/WNL.0000000000207663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。